{"id":"W3197001173","doi":"10.1093/rheumatology/keab685","title":"Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study","year":2021,"lang":"en","type":"article","venue":"Lara D. Veeken","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto Western Hospital; University of Toronto","funders":"Gilead Sciences","keywords":"Medicine; Double blind; Placebo; Lupus erythematosus; Dermatology; Cutaneous Lupus Erythematosus; Internal medicine; Physical therapy; Immunology; Pathology; Alternative medicine; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002286752,0.001193815,0.003096064,0.0003980612,0.0003849464,0.0009600665,0.0008412179,0.002038885,0.00743727],"category_scores_gemma":[0.001464393,0.0005946287,0.001259643,0.0003868776,0.0007868505,0.0009159471,0.0002697,0.001872414,0.0007866586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004318317,"about_ca_system_score_gemma":0.0008652721,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002529479,"about_ca_topic_score_gemma":0.0007869679,"domain_scores_codex":[0.9993846,0.0003195667,0.00004873556,0.0001049499,0.00006609384,0.00007597205],"domain_scores_gemma":[0.9994235,0.0001555723,0.0001646014,0.00004108507,0.00004822223,0.0001669437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9390844,0.01344671,0.0006724659,0.002652546,0.001413686,0.0001166405,0.00004699236,0.000227568,0.009786,0.0001238925,0.001303571,0.0311255],"study_design_scores_gemma":[0.9411718,0.05603151,0.001053542,0.00004909508,0.0003070422,0.00006261452,0.00001057507,0.0001758664,0.0003413841,0.00005625188,0.000731396,0.000008832332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9564576,0.02371163,0.001800633,0.001247516,0.00103609,0.01107717,0.001334695,0.0002883267,0.003046486],"genre_scores_gemma":[0.97021,0.009471287,0.002725451,0.002899702,0.001005307,0.009478535,0.001058482,0.00003000643,0.00312124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00743727,"threshold_uncertainty_score":0.02488011,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04324566138564291,"score_gpt":0.3481351228482052,"score_spread":0.3048894614625623,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}